Research and Markets (http://www.researchandmarkets.com/research/e3e906/aneurysm_flow_modu)
has announced the addition of the "Aneurysm Flow Modulating Device
Market Current Status & Strategic Opportunities" report to their
offering.
“Aneurysm Flow Modulating Device
Market Current Status & Strategic Opportunities”
With ev3 valuing Chestnut Medical Pipeline Embolization Device
Technology at $150 million and forecasting a market of $350 million for
cerebral flow diversion devices by 2013, the floodgates for innovation
in the paradigm-shifting field of aneurysm flow modulation have just
been blown away.
The unmet medical need is vast, from difficult to coil wide-necked
cerebral aneurysms to hard-to-repair thoraco-abdominal aortic aneurysms,
and the technology is proving itself to be safe, logical and accessible
to small & medium size entrepreneurial start-ups.
Endovascular treatment of aneurysms has evolved substantially over the
past two decades, transitioning from an investigational therapy into
routine clinical practice and ultimately emerging as the treatment of
choice for many lesions.
To date, endovascular therapy has been almost exclusively focused on
filling the aneurysm sac with embolic material (coils or liquid
embolics) or bridging the aneurysm with a covered stent (Stent Graft).
The idea behind the use of endovascular flow modulating (diverting)
devices as monotherapy for endovascular aneurysm repair stems from the
concept that a low porosity stent bridging the aneurysm neck modulates
hemodynamic flow away from the vortex and streamlines blood flow within
parent artery.
Dedicated flow diverting devices for eliminating cerebral aneurysms from
circulation without the need for coils have already been cleared for
marketing in Europe since mid-2008 and dedicated flow modulating devices
for peripheral aneurysm repair entered the European market in 2009.
The market for aneurysm flow modulating devices is still in the
embryonic stage with windows of opportunities opening for early
entrants. Due to the novelty of the paradigm-shifting technology, little
notice was taken of the market potential by large multinationals until
ev3 adopted, and started publicizing the technology.
The hypothesis that wall shear stress modulates endothelial cellularity
is gaining increasing support from researchers in the field. However,
few companies are currently developing dedicated flow modulating devices
with designs that take into consideration hemodynamic flow and
endothelial growth dynamics.
Aneurysm Flow Modulating Device Market - Current Status & Strategic
Opportunities is the first report to cover the market of flow-diverting
devices for aneurysm reconstruction and repair.